Full-Time

Medical Science Liaison

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Biotechnology
Healthcare

Compensation Overview

$132.7k - $165kAnnually

+ Bonus + Incentives + Restricted Stock Units

Mid, Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Terminal scientific and/or clinical degree – Ph.D., M.D., Pharm.D., and D.O.
  • At least 3 years of clinical or industry experience, preferably with an oncology/endocrinology focus.
  • Deep understanding of the peer-review publication process as demonstrated by at least one first-author article published in peer-reviewed journals.
  • Advanced understanding of the genetic basis for disease and modern genomic techniques is critical for success in this role.
  • Prior experience as an MSL in introducing and supporting novel diagnostic assays is desired.
  • Overall solid written and verbal communication skills to convey complex study results to audiences with varying degrees of scientific/clinical knowledge.
  • Outstanding interpersonal skills in understanding HCP needs and situational awareness to adapt content and communication style in real-time.
  • Team player working in synergy with marketing and sales team members providing accurate, comprehensive, and timely scientific and clinical support.
  • Demonstrating customer-centricity and passion for helping patients.
  • Familiarity with statistical methodologies.
  • A detail-oriented, organized self-starter with a strong ability to prioritize workload.
  • Location in proximity to airport hub and ability to travel within the defined region.
Responsibilities
  • Proactively identify, develop, and maintain strong relationships with academic and community physicians to promote understanding and adoption of Veracyte’s diagnostic tests.
  • Identify KOLs, stimulate investigator-initiated studies, and support them until study completion and article publication.
  • Provide tailored presentations to external HCPs at the request of sales team members.
  • Support the medical affairs team in collecting real-world evidence supporting the clinical utility of Veracyte’s tests.
  • Create and implement strategies supporting product improvements in collaboration with medical affairs, research and development, managed care, and sales teams.
  • Critically review the literature and build educational materials for external HCP and internal stakeholders.
  • Serve as a primary scientific and clinical resource to the marketing and sales team members providing medical updates, journal clubs, and MSL office hours.
  • Assist the managed care team in setting up applications for medical coverage by providing up-to-date scientific and clinical information supporting the clinical utility of Veracyte’s tests.
  • Provide conference coverage supporting the sales team and prepare a post-conference summary of relevant talks to the leadership team.

Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples like nasal swabs or tissue biopsies, providing insights into the presence and progression of cancer. This allows healthcare providers, such as hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte stands out from competitors by focusing on non-invasive testing methods and continuously expanding its product offerings through research and clinical validation. The company's goal is to improve cancer diagnosis accuracy, leading to better patient outcomes and more efficient healthcare resource use.

Company Stage

IPO

Total Funding

$69.4M

Headquarters

San Francisco, California

Founded

2008

Growth & Insights
Headcount

6 month growth

5%

1 year growth

7%

2 year growth

12%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increasing demand for personalized medicine boosts Veracyte's genomic diagnostics market.
  • AI integration enhances the accuracy and speed of Veracyte's cancer diagnostics.
  • Regulatory support is improving, facilitating faster market entry for Veracyte's tests.

What critics are saying

  • Potential bias in genomic tests due to lack of diversity in development populations.
  • Upcoming MRD assay launch may face reimbursement challenges with commercial payers.
  • ClearLab's 2026 launch may encounter significant competition and market penetration challenges.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection.
  • The Decipher Prostate test is prognostic for prostate cancer progression in active surveillance.
  • Veracyte's whole-transcriptome approach provides comprehensive data for urologic cancer research.

Help us improve and share your feedback! Did you find this helpful?